MaxCyte Stock

MaxCyte Shareholder Yield

Delisted

The Shareholder Yield of MaxCyte (MXCT) as of Aug 5, 2026 is 2.68 %. In the previous year, Shareholder Yield was 2.79 % — a change of -4.06% (lower).

Shareholder Yield

2.68 %

YoY

-4.06%

Last updated:

Shareholder Yield of MaxCyte is 2026 2.68 % . Shareholder Yield of MaxCyte was 2025 2.79 % . It decreases by -4.06% lower compared to the previous year.
Access this data via the Eulerpool API

MaxCyte Stock analysis

What does MaxCyte do? MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MaxCyte stock

Shareholder Yield of MaxCyte is 2.68 % in 2026.

Shareholder Yield of MaxCyte changed from 2.79 % to 2.68 %, representing a -4.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Shareholder Yield MaxCyte since 2006 – with annual values, charts, and detailed analysis.

Shareholder yield combines dividend yield and buyback yield to show the total cash return to shareholders. It captures both dividends and share repurchases.

To evaluate Shareholder Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Shareholder Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Shareholder Yield's MaxCyte with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — MaxCyte

All Key Metrics — MaxCyte